First in Class First in Man Compounds Targeting Tumor Bioenergetics from Lab Bench to Clinical Trials: Working with the FDA to meet Guidelines

Sign for Notice Everyday

Home Post Event 2025Event 2026Event By Topic By Country Contact

Our Sponsors

First in Class First in Man Compounds Targeting Tumor Bioenergetics from Lab Bench to Clinical Trials: Working with the FDA to meet Guidelines - Webinar By GlobalCompliancePanel

Website http://alturl.com/m6pjz | Edit Freely

Category online training, Tumor Bioenergetics,Lab Bench,Clinical Trials,FDA Guidelines,FDA regulation,nanotechnology,cancer chemotherapeutics

Deadline: June 27, 2012 | Date: June 28, 2012

Venue/Country: Online Training, U.S.A

Updated: 2012-05-28 21:13:32 (GMT+9)

Call For Papers - CFP

Overview: Many anticancer drugs are not tumor selective. For chemotherapy the lack of drug and disease specificity and need for higher dosing leads to adverse and serious adverse events that may be dose limiting. Preventing a therapeutic level to be achieved in a patient.

An extensive list of unwanted toxicities, some of which may be permanent and serious adverse events that may be fatal are well known. We have been developing a platform of first in class first in man compounds that demonstrate selective uptake into tumor cells. Safer more effective treatment has been demonstrated in xenograft models. This Webinar will discuss the present and future development challenges and strategies in the context of novel drugs with selective delivery properties entering the FDA process for consideration and evolution from clinical research to drug product development.

Why should you attend: To establish and contribute to an enhanced understanding of novel drugs targeting tumor metabolism, more specifically bioenergetics and FDA guidelines for new chemical entities. Unlike many cancer chemotherapeutics these new drugs are selectively taken up into cancer cells. This being of critical importance as the pharmaceutical being delivered, targets the intracellular organelle mitochondria. Such novel “smart drug” delivery features also requiring discussion and consideration of preclinical approaches that would support clinical development in man with the potential need for a clinical research period wherein during clinical studies, how current disease progression measurement methods (CT/PET and RECIST) might be used along with the potential identification of biomarkers and companion diagnostics that could be validated in retrospective studies. The latter possibly being linked to delivery technology or active pharmaceutical mechanism of action or to disease progression markers.

Areas Covered in the Session:

Introduction into nanotechnology drug delivery and needs for improvement

Review of relevant FDA regulation, guidelines and points to consider for manufacturing and drug product composition

Clinical research to support clinical development and protocol preparation for human study working with the FDA

Clinical development planning and path to approvals

Who Will Benefit:

Formulation Scientists and Researchers

Regulatory Affairs Managers, Directors and VPs

Quality Managers, Directors and VPs

Manufacturing Managers, Directors and VPs

Strategic Planning Managers, Directors and VPs

Price List:

Live : $245.00

Corporate live : $995.00

Recorded : $295.00

webinarsglobalcompliancepanel.com

http://www.globalcompliancepanel.com

Phone: 800-447-9407

Fax: 302-288-6884

Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.